Literature DB >> 9457605

Impact of Acinetobacter spp. in intensive care units in Great Britain and Ireland.

H Humphreys1, K J Towner.   

Abstract

Acinetobacter spp. are of increasing importance as hospital pathogens in intensive care units (ICUs) but it is unclear what clinical impact these bacteria have in Great Britain and Ireland. A survey was carried out by questionnaire on the impact of Acinetobacter in ICUs and the laboratory methods used to identify and type isolates. There were 70 respondents, of whom 25 reported that Acinetobacter had not been recovered from ICU patients within the previous 12 months. The remaining 45 respondents reported that the respiratory tract was the most common site from which these bacteria were isolated, but they were currently endemic in one ICU only. There were considerable differences in methods used to identify Gram-negative bacilli recovered from ICU patients, which may partly explain differences in the reported prevalence of isolates between centres, and 12 laboratories attempted to type isolates by a range of techniques. The availability and use of agreed antibiotic policies specific for ICUs may be particularly important in prevention and control where infection with Acinetobacter is prevalent.

Entities:  

Mesh:

Year:  1997        PMID: 9457605     DOI: 10.1016/s0195-6701(97)90144-4

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  7 in total

1.  Bacterial identification, clinical significance, and antimicrobial susceptibilities of Acinetobacter ursingii and Acinetobacter schindleri, two frequently misidentified opportunistic pathogens.

Authors:  Laurent Dortet; Patrick Legrand; Claude-James Soussy; Vincent Cattoir
Journal:  J Clin Microbiol       Date:  2006-10-18       Impact factor: 5.948

2.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

Review 3.  Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence.

Authors:  Drosos E Karageorgopoulos; Theodore Kelesidis; Iosif Kelesidis; Matthew E Falagas
Journal:  J Antimicrob Chemother       Date:  2008-04-24       Impact factor: 5.790

4.  A retrospective study of the incidence, clinical characteristics, identification, and antimicrobial susceptibility of bacteremic isolates of Acinetobacter ursingii.

Authors:  Chun-Hsiang Chiu; Yi-Tzu Lee; Yung-Chih Wang; Ti Yin; Shu-Chen Kuo; Ya-Sung Yang; Te-Li Chen; Jung-Chung Lin; Fu-Der Wang; Chang-Phone Fung
Journal:  BMC Infect Dis       Date:  2015-09-30       Impact factor: 3.090

5.  Complete Genome Sequence of Acinetobacter schindleri SGAir0122 Isolated from Singapore Air.

Authors:  Carmon Kee; Ana Carolina M Junqueira; Akira Uchida; Rikky W Purbojati; James N I Houghton; Caroline Chénard; Anthony Wong; Megan E Clare; Kavita K Kushwaha; Deepa Panicker; Alexander Putra; Nicolas E Gaultier; Balakrishnan N V Premkrishnan; Cassie E Heinle; Vineeth Kodengil Vettath; Daniela I Drautz-Moses; Stephan C Schuster
Journal:  Genome Announc       Date:  2018-06-28

6.  Clinical outcomes of tigecycline in the treatment of multidrug-resistant Acinetobacter baumannii infection.

Authors:  Jung Ar Shin; Yoon Soo Chang; Hyung Jung Kim; Se Kyu Kim; Joon Chang; Chul Min Ahn; Min Kwang Byun
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

7.  Draft Genome Sequencing of an Acinetobacter ursingii Isolate from Healthy Human Skin, Carrying Multidrug Resistance Genes.

Authors:  Lenka Palkova; Gabriel Minarik; Katarina Soltys
Journal:  Genome Announc       Date:  2018-05-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.